Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125721 · ClinicalTrials.gov registry record · Phase 4
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02125721 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT02125721, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.
Interventions
- DRUG Tiopronin 1g per day
- DRUG Tiopronin 2g per day
- DRUG Tiopronin 3g per day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02125721
The ClinicalTrials.gov registry entry for NCT02125721 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tiopronin 1g per day is the first listed.
NCT02125721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02125721 about?
NCT02125721 is a clinical study titled "Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria". The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help gui...
What is the current status of trial NCT02125721?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2012-06. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02125721?
The interventions under investigation include: Tiopronin 1g per day (DRUG), Tiopronin 2g per day (DRUG), Tiopronin 3g per day (DRUG).
Who is sponsoring clinical trial NCT02125721?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.